Low molecular weight heparin in acute coronary syndromes (Q34027303)

30 July 2017

1 reference

title

Low molecular weight heparin in acute coronary syndromes (English)

1 reference

30 July 2017

main subject

acute coronary syndrome

1 reference

Cannon CP

1

1 reference

30 July 2017

publication date

1 September 1999

1 reference

Current cardiology reports

30 July 2017

published in

1 reference

30 July 2017

volume

1

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

206-211

1 reference

The multiple complexes formed by the interaction of platelet factor 4 with heparin

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11886-999-0024-X

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-999-0024-X

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-999-0024-X

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11886-999-0024-X

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

21 January 2018

1 reference

12 December 2020

A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery

1 reference

12 December 2020

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

12 December 2020

Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction. A dose - finding study

1 reference

12 December 2020

Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group

1 reference

12 December 2020

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

12 December 2020

Heparin binding to plasma proteins, an important mechanism for heparin resistance

1 reference

12 December 2020

Persistent thrombin generation in humans during specific thrombin inhibition with hirudin

1 reference

12 December 2020

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

12 December 2020

Reactivation of unstable angina after the discontinuation of heparin

1 reference

12 December 2020

Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome

1 reference

12 December 2020

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

12 December 2020

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group

1 reference

12 December 2020

Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators

1 reference

12 December 2020

Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).

1 reference

12 December 2020

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

12 December 2020

Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma

1 reference

12 December 2020

Anticoagulant treatment of unstable angina

1 reference

12 December 2020

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

12 December 2020

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

12 December 2020

1 reference

12 December 2020

Optimizing the Treatment of Unstable Angina.

1 reference

12 December 2020

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

12 December 2020

Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin

1 reference

12 December 2020

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

12 December 2020

Aspirin, heparin, or both to treat acute unstable angina

1 reference

12 December 2020

Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

1 reference

12 December 2020

10.1007/S11886-999-0024-X

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1048571609

0 references

1 reference